Consenso de expertos sobre recomendaciones basadas en evidencia para el diagnóstico, tratamiento y seguimiento de enfermedad de Fabry en pediatría

Background: Fabry disease (FD) is a rare X-linked disorder disease characterized by the deposit glycosphingolipids in lysosomes due to a deficiency in the production of alpha galactosidase A (α-Gal A) enzyme. Despite its low frequency, this disease has a serious impact on quality of and life expecta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista ciencias de la salud 2023-10, Vol.21 (3)
Hauptverfasser: Baquero Rodríguez, Richard, Trimarchi, Hernán, Martínez Cáceres, Lyda Esperanza, Valencia, Maylin, Liern, Miguel, Cárdenas Aguilera, Juan Guillermo, Gutiérrez Sepúlveda, María Paula, Estévez Capacho, Mayra Alexandra, Carrascal Guzmán, Martha, Cerón Rodríguez, Magdalena, Ospina-Lagos, Sandra Yaneth, Rodríguez, Edisson, Mateus Arbeláez, Heidi, Chacon, Kelly Rocio, Fainboin, Alejandro, Reina Ávila, María Fernanda, Serrano Gayubo, Ana K, Germain, Dominique P, Cabrera, Gustavo, Prieto, Juan Carlos, Politei, Juan Manuel, Rodríguez Cuéllar, Carmen Inés
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Fabry disease (FD) is a rare X-linked disorder disease characterized by the deposit glycosphingolipids in lysosomes due to a deficiency in the production of alpha galactosidase A (α-Gal A) enzyme. Despite its low frequency, this disease has a serious impact on quality of and life expectancy. Objective: To make evidence-informed recommendations for the diagnosis and treatment of FD in pediatric patients (< 18 years of age). Methods: A literature review was carried out in databases and gray literature from 2010, including clinical practice guidelines, systematic reviews, primary studies. The quality of evidence was assessed according to the type of evidence. The recommendations were submitted to expert consensus using the modified Delphi methodology. The agreement was defined from 80%. Conclusions: The recommendations resulting from this expert consensus will allow the standardization of the provision of care to pediatric patients with FD in Colombia and Latin-America, as well as of clinical decisión making in the management of the disease. Also, it is worth noting that making a timely diagnosis ensures a reduction in the impact that this disease might have on the quality of life of both patients and their families. Keywords: Fabry Disease; Child; Diagnosis; Therapeutics; Biomarkers. Antecedentes: La enfermedad de Fabry (EF) é uma enfermedad rara associada a X secundaria al depósito lisossomal de glicoesfingolípidos debido à deficiência da enzima alfa galactosidasa A (α-Gal A). A pesar de sua baixa frequência, é uma condição que afeta a qualidade de vida dos pacientes e diminui sua esperança de vida. Objetivo: Generar recomendações registradas Objetivos em evidência para o diagnóstico e tratamento de pacientes pediátricos (de 8 anos) com EF. Métodos: Realizou-se uma revisão de literatura em bases de dados e literatura gris a partir de 2010, incluindo guias de prática clínica, revisões sistemáticas, estudos primários. A qualidade de evidência se avalia de acuerdo com o tipo de evidência. As recomendações são algumas sobre o consenso de especialistas sobre a metodologia da Delphi modificada. O preço é definido a partir de 80%. Resultados: A partir da análise da evidência coletada, se formula um total de 45 recomendações para tratamento, diagnóstico e tratamento do paciente pediátrico com enfermedad de Fabry. El painel revisor estuvo conformado por uma vez expertos en el tema. As recomendações foram aprovadas com pontuações entre 82,3% e 100%. Concl
ISSN:1692-7273
2145-4507
2145-4507
DOI:10.12804/revistas.urosario.edu.co/revsalud/a.12504